FocalTherics, legally EDAP TMS S.A., is a France-based medical technology company that develops, manufactures, and markets minimally invasive, robotic high-intensity focused ultrasound (HIFU) devices for urology. Its flagship product, Focal One, uses robotic HIFU to ablate localized prostate tumors without surgery, radiation, or needles. The company generates a recurring revenue stream from Focalpak single-use consumables, leases, and service, alongside the sale of capital systems.
In June 2026, the company rebranded from EDAP TMS to FocalTherics and adopted the FOCL ticker on Nasdaq, refocusing the business around Focal One after winding down its lithotripsy (ESWL) and distribution lines into discontinued operations. As of the third quarter, its worldwide installed base stood at 192 systems, including 98 in the United States. Investors follow the stock for adoption of focal therapy, expanding reimbursement coverage, and procedure volume growth. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Over the last 30 days, FOCL declined roughly 41%, falling from a closing price near $4.37 in late October to approximately $2.57. The stock was rangebound in the low-to-mid $4 area through most of October before breaking down sharply in November following its quarterly report.
The trailing quarter tells a similar story. From a level near $4.24 in mid-August, the shares have fallen about 39%. After peaking near $4.74 in late September, the stock gave back its gains and moved decisively lower in November, leaving the quarter and the 30-day window both firmly in negative territory.
The dominant catalyst was the company's third-quarter 2026 earnings report, released November 5. Revenue rose about 26% year over year to $9.8 million, but the result came in below consensus expectations by roughly $1.7 million because three anticipated Focal One system sales did not close by quarter-end. Management explained that hospital value-analysis committee processes ran longer due to summer seasonality in capital purchasing, and one transaction was delayed by bank financing at quarter-end.
The company also narrowed its full-year 2026 revenue guidance to $50–$52 million from $50–$54 million. Investors reacted by sending the stock down more than 20% in a single session, and the selling pressure continued through the following weeks. A sell-side analyst subsequently lowered the price target to $8 from $10 while maintaining a Buy rating. Positive details in the report — including 32% U.S. procedure volume growth, a gross margin increase to 51.4%, and a strengthened cash position of $56.3 million — were outweighed by the headline miss and the reduced outlook. From what I see, the timing issues appear temporary rather than structural.
Over the past three months, the broader narrative has centered on a company in transition. The June rebranding to FocalTherics refocused the business exclusively on robotic focal therapy, and an August equity offering strengthened the balance sheet. Through the summer and early fall, the stock held up near $4.00–$4.40, supported by strong procedure growth and improving reimbursement, including a National Comprehensive Cancer Network (NCCN) upgrade of HIFU to category 2A for radiorecurrent prostate cancer and new commercial payer coverage policies.
That momentum was interrupted by the third-quarter earnings miss, which exposed the lumpiness of capital-equipment sales in a business where a handful of system deals can materially shift a quarter. While recurring consumables and procedure volumes continued to grow, the narrowed guidance and questions around capital-sales timing drove a sustained derating through November.
Looking ahead, the key near-term catalyst is the fourth-quarter report, which management has historically described as its largest quarter for capital-system placements. Whether the three delayed sales close as expected will be a central focus. Longer term, investors are watching the HIFUSA Phase III randomized trial comparing Focal One to active surveillance, with data expected in early 2027, as well as progress expanding Focal One into benign prostatic hyperplasia (BPH) and endometriosis indications.
Other factors include the pace of reimbursement and coverage expansion for salvage therapy, procedure volume trends across the installed base, hospital capital budgets and financing conditions, currency effects on the euro-denominated business, and the competitive landscape in prostate focal therapy. These variables, rather than any single event, will likely shape how the stock trades from here. I’m watching this closely for any signs of stabilization in capital sales timing.
In my analysis of names like FOCL, I often turn to Tickeron’s platform for quantitative context. The Trending AI Robots section highlights a curated selection of top-performing automated trading strategies across hundreds of bots that trade thousands of tickers. Only those demonstrating standout performance and current relevance appear in the featured section, allowing users to compare different automated approaches side by side. This can offer useful data-driven signals alongside traditional fundamental research.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
FOCL moved below its 50-day moving average on November 05, 2026 date and that indicates a change from an upward trend to a downward trend. In 27 of 30 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 90%.
The Momentum Indicator moved below the 0 level on November 06, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on FOCL as a result. In 72 of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 79%.
The Moving Average Convergence Divergence Histogram (MACD) for FOCL turned negative on November 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 40 similar instances when the indicator turned negative. In 33 of the 40 cases the stock turned lower in the days that followed. This puts the odds of success at 82%.
The 50-day moving average for FOCL moved below the 200-day moving average on October 19, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where FOCL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
The Aroon Indicator for FOCL entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator entered the oversold zone -- be on the watch for FOCL's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 8 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +4.08% 3-day Advance, the price is estimated to grow further. Considering data from situations where FOCL advanced for three days, in 185 of 242 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
FOCL may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 61 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-48.608) is normal, around the industry mean (14.423). P/E Ratio (-3.192) is within average values for comparable stocks, (11.188). FOCL's Projected Growth (PEG Ratio) (8.100) is very high in comparison to the industry average of (2.016). Dividend Yield (0.000) settles around the average of (0.134) among similar stocks. P/S Ratio (1.919) is also within normal values, averaging (4.260).
The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating fairly steady price growth. FOCL’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. FOCL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 74, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a developer of minimally invasive medical devices for urological diseases
Industry MedicalDistributors